Summaries by Inventor Sivapackiam, Jothilingam
Sharma, Vijay ; Sivapackiam, Jothilingam
T-019479
— T-019479 Tissue-penetrating PET radiotracer for non-invasive detection of ROS and inflammation. Technology Description 18F-fluorodeoxyglucose (18F-FDG) has long been used for the diagnosis of neoplasms, and recently Alzheimer’s disease. However, 18F-FDG signals are often not correlated with…
PET/SPECT Agents for Applications in Biomedical ImagingPiwnica-Worms, David ; Sharma, Vijay ; Sivapackiam, Jothilingam
T-010438
— Background Coronary heart disease is the primary cause of death in the Unites States. Though myocardial perfusion imaging in hospitals has mostly involved the use of 99mTc-Sestamibi and similar agents for diagnosing heart disease, there is an increased desire for PET perfusion agents. The global in…
Design and Development of Organomedicinals for Imaging and Treatment of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia (FTD)Guruswami, Sundaram ; Sharma, Vijay ; Sivapackiam, Jothilingam
T-016665
— Background Frontotemporal Dementia (FTD) is the second most common form of non-Alzheimer’s dementia in the population under 65 years old. FTD represents approximately 20% of all dementias and onset normally appears in the mid to late 50s. Clinically FTD is characterized by a progressive neur…
PET Radiotracers Capable of Crossing the Blood Brain Barrier and Detecting Reactive Oxygen SpeciesSatham, Lakshminarayana ; Sharma, Vijay ; Sivapackiam, Jothilingam
T-020300
— T-020300 PET Radiotracers Capable of Crossing the Blood Brain Barrier and Detecting Reactive Oxygen Species Technology Description Reactive Oxygen Species (ROS) is known to contribute to the pathogenesis of neuropathological conditions such as Alzheimer’s disease and cancer. However, there…
PET tracers for detection of early stage Alzheimer’s diseaseGuruswami, Sundaram ; Sharma, Vijay ; Sivapackiam, Jothilingam
T-013525
— Technology Description Researchers at Washington University in St. Louis have developed PET radiotracers to image amyloid beta (A-beta) at early stages of Alzheimer’s Disease (AD). For AD treatment to be effective, it may have to be administered during the preclinical stage. As such, there i…
Design and Development of Organomedicinals for Imaging and Treatment of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia (FTD)Guruswami, Sundaram ; Sharma, Vijay ; Sivapackiam, Jothilingam
T-016665
— Background Frontotemporal Dementia (FTD) is the second most common form of non-Alzheimer’s dementia in the population under 65 years old. FTD represents approximately 20% of all dementias and onset normally appears in the mid to late 50s. Clinically FTD is characterized by a progressive neur…
PET/SPECT Agents for Applications in Biomedical ImagingPiwnica-Worms, David ; Sharma, Vijay ; Sivapackiam, Jothilingam
T-010438
— Background Coronary heart disease is the primary cause of death in the Unites States. Though myocardial perfusion imaging in hospitals has mostly involved the use of 99mTc-Sestamibi and similar agents for diagnosing heart disease, there is an increased desire for PET perfusion agents. The global in…
